Celcuity Inc. is a biotechnology company that develops targeted therapies for cancer patients in the United States, using a patient's living tumor cells. Gedatolisib is its leading drug candidate, which selectively targets PI3K and mammalian target of rapamycin and focuses on the treatment of advanced or metastatic breast cancer patients. The company is also developing CELsignia MP test to measure the signaling activity of HER2, c-Met, and PI3K in breast and ovarian tumor cells.